NCT01391611

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

A Phase II Study of Pazopanib in Patients With Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Kristen Ganjoo · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to gather information about the safety (any harmful effects) and effectiveness (usefulness) of Pazopanib in the treatment of Gastrointestinal Stroma Tumors (GIST) that cannot be treated by surgery or has spread to other organs. The Food and Drug Administration (FDA) have approved Pazopanib for the treatment of advanced kidney cancer but it is not approved for the treatment of GIST. The investigators hope to learn about the safety and usefulness (effectiveness) of Pazopanib for patients with GIST. Primary Objective: Non-progression rate based on RECIST criteria (CR+PR+SD) Secondary Objectives: * Response per Choi criteria * 6 month progression-free survival * Safety and tolerability

Conditions

• Gastrointestinal Stromal Tumor (GIST)

Interventions

Type	Name	Description
DRUG	Pazopanib	800 mg; PO

Timeline

• Start date: 2011-07-01
• Primary completion: 2013-06-01
• Completion: 2013-12-01
• First posted: 2011-07-12
• Last updated: 2017-04-07
• Results posted: 2017-04-07

Locations

2 sites across 1 country: United States